Premature Labor – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Premature Labor Market Outlook

Thelansis’s “Premature Labor Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Premature Labor treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Premature Labor Overview

Preterm labor, defined as childbirth occurring between 20 0/7 weeks and 36 6/7 weeks of gestation, can be further categorized into early preterm (birth before 33 weeks) and late preterm (birth between 34 and 36 weeks). Various factors contribute to preterm labor, including stress, infection, placental abruption, placenta previa, substance use, history of preterm birth or abortion, inadequate prenatal care, smoking, maternal age below 18 or above 40, poor nutrition, low body mass index, fetal anomaly, fetal growth restriction, oligohydramnios, polyhydramnios, vaginal bleeding, premature preterm rupture of membranes (PPROM), and environmental factors. Labor involves three main components: cervical changes, persistent uterine contractions, and activation of the decidua and membranes. The distinction between term labor and preterm labor lies in the physiological nature of the former and the pathological nature of the latter. Preterm labor can occur acutely or develop gradually over several weeks. Mothers presenting with signs and symptoms of preterm labor before 34 weeks of gestation are typically hospitalized. To inhibit labor in preterm labor with intact membranes, tocolytic drugs are administered for up to 48 hours. Guidelines suggest considering tocolytics between 22 and 34 weeks of gestation, given no contraindications. Preterm labor poses increased risks of cardiovascular morbidity and mortality for mothers, although the reasons for this association remain unclear, and the effects are often observed years after delivery. Infants born due to preterm labor are at risk of impaired neurodevelopmental outcomes, including cognitive impairment, motor deficits, cerebral palsy, and vision and hearing impairments. Neonatal complications associated with preterm labor include necrotizing enterocolitis, intraventricular hemorrhage, bronchopulmonary dysplasia, retinopathy of prematurity, poor growth, and congenital anomalies.

• In 2021, the United States recorded 383,979 preterm births, accounting for 10.5% of all live births.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: